Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Survey aims to uncover hidden barriers to esophageal cancer screening

NCT ID NCT04408105

Knowledge-focused Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study surveyed over 700 primary care doctors, gastroenterologists, and patients across seven U.S. health systems. The goal was to find out what knowledge gaps, attitudes, and practical barriers prevent people from getting screened for Barrett's esophagus, a condition that can lead to esophageal cancer. By identifying these obstacles, researchers hope to design better screening programs in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point to better ways to encourage screening for Barrett's esophagus, potentially catching esophageal cancer earlier.
What could go wrong
This is an observational survey study, not a treatment trial. It identifies barriers but does not test any intervention, so its direct impact on patient outcomes is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

725 people

The number who actually took part.

Started

Feb 2020

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

1. We will include patients with a diagnosis of gastroesophageal reflux disease (GERD) who have at least one outpatient clinic visit at a participating site. Patients will be identified through an administrative query of the electronic medical record by ICD-10 codes for GERD (K21.0 and K21.9) as well as through a review of the upcoming clinic schedule. Patients with prior diagnosis of BE/EAC or language other than English will be excluded. Across the 7 sites, we plan to enroll 500 patients. 2. This study will include PCPs and gastroenterologists at participating sites. Across the 7 participating centers, we plan to enroll 100 gastroenterologists and 400 PCPs.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Patient Eligibility Criteria Inclusion Criteria: * Patients identified by ICD-10 codes for GERD (K21.0 and K21.9) AND * Have had at least one outpatient clinic visit at a participating site Exclusion Criteria: * Prior diagnosis of BE/EAC * Non-English speaking 2. Provider Eligibility Criteria Inclusion Criteria: * Provider must be a PCP and/or gastroenterologist AND * Must be at a participating site

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barrett's esophagus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Barrett esophagus gastroesophageal reflux disease esophageal adenocarcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Barrett's esophagus Esophagus adenocarcinoma Gastroesophageal reflux disease

Contacts and locations

Locations

  • Denver Health Medical Center

    Aurora, Colorado, 80045, United States

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Parkland Health and Hospital System

    Dallas, Texas, 75235, United States

  • Pennsylvania Hospital

    Philadelphia, Pennsylvania, 19104, United States

  • Pennsylvania Presbyterian Hospital

    Philadelphia, Pennsylvania, 19104, United States

  • University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.